What's New at Qiming
• Unisound (SEHK:9678), a pioneer in the industrialization of AI technologies in China, has successfully debuted on the Hong Kong Stock Exchange.
Qiming Venture Partners has been a long-standing investor in Unisound, first participating in the company's Series A funding round in 2013. Over the past decade, Qiming has continued to support Unisound through its Series B and D1 rounds.
"As an early investor in Unisound, we are delighted to have witnessed its remarkable leap from technological exploration to a successful IPO," said Duane Kuang, Founding Managing Partner of Qiming Venture Partners. "Unisound's listing marks a new chapter for the company and highlights the significant progress in the industrialization of AI in China. We look forward to seeing Unisound continue to push the boundaries of innovation, accelerate talent acquisition and development, and showcase the strength of Chinese AI companies. At Qiming, we remain committed to supporting companies like Unisound that combine deep technological expertise with strong commercial vision and long-term growth potential."
• At the Qiming Venture Partners 16th Annual RMB Fund Meeting and Investor Summit, Duane Kuang, Founding Managing Partner of Qiming Venture Partners, sat down with Zhou Jian, Chairman of the Board, Executive Director, and CEO of UBTECH (SEHK:9880), for a conversation on the future of the humanoid robotics industry.
Their discussion explored the current state of the industry, emerging application scenarios, and the potential of embodied intelligence to drive both cost efficiency and operational productivity. Zhou Jian also shared insights into UBTECH’s core competitive advantages.
Commenting on the growing number of new entrants in the space, Zhou Jian emphasized that UBTECH welcomes both collaborators and competitors, noting that the humanoid robotics market is vast and full of diverse opportunities. He pointed out that embodied intelligence requires robots to autonomously perceive, understand, and execute tasks in complex environments, posing significant technical challenges. “Whether you're an early pioneer or a new challenger, only those who achieve true technological breakthroughs and deliver real-world applications will stand the test of time. We believe that by staying committed and doing the hard but right things, opportunity will follow,” said Zhou Jian.
Speaking on the economics of commercialization, Duane noted that deploying just one or two humanoid robots as a factory demo may be feasible, but only large-scale deployment can unlock their full value.
• In a recent interview with Shanghai Securities News, William Hu, Managing Partner at Qiming Venture Partners, shared his perspectives on policy trends, company strategy shifts, and emerging technologies, outlining the core logic and development of investments in innovative drugs.
William emphasized that the success of M&A often hinges on an entrepreneur’s ability to shift from a traditional focus on control to a broader, ecosystem-driven mindset. This transition requires not only a deep understanding of the target company’s core value, whether in technology, pipeline, or market position, but also a clear and executable roadmap for integration and joint development. He also highlighted the importance of a fair and forward-looking valuation, one that reflects the long-term potential created through collaboration, rather than being anchored solely to short-term financial metrics. Entrepreneurs, he noted, must be able to envision the expanded opportunities that successful integration can bring.
Portfolio Highlights
Portfolio ESG
• At the launch of the Silver Smile Program and Children's Dental Care Project in Jiaxiang, Shandong, Bondent and Dr. CLEAR ALIGNER joined as core partners, signing a strategic partnership to provide technology backbone and hardware support.
Financing
• Longbio Pharma has raised over RMB 200 million in its Series C round, co-led by Qiming Venture Partners. The funds will support the Phase 3 trial and commercialization preparation of LP-003, as well as the Phase 2 development of LP-005.
• TINGSN has completed a nearly RMB 100 million Series B+ round. Qiming Venture Partners continued its investment. Funds will accelerate 4D ICE R&D, clinical deployment, and preparations for mass production. TINGSN also completed China's first 4D ICE clinical study.
Technology
• WeRide (NASDAQ:WRD) has signed a MoU with Dubai’s Roads and Transport Authority (RTA) and Uber to begin autonomous vehicle pilot operations in Dubai via the Uber App this year—with safety drivers onboard initially and full driverless rollout planned for 2026.
The company has partnered with Renault Group, a premium partner of Roland-Garros, for the second consecutive year, to provide a Level-4 autonomous minibus shuttle service during the 2025 Grand Slam tournament on the iconic clay courts.
• UBTECH (SEHK:9880) and Foxconn launched an embodied intelligence robot skills training program, marking a key milestone in their strategic partnership to advance applications in smart manufacturing and develop future talent.
The company launched its latest commercial humanoid robot solution for smart exhibitions. Powered by Walker C, it blends technology and culture to enable next-generation intelligent service infrastructure.
• Six versions of the 2026 Leapmotor C16 feature advanced perception components, including high-performance lidar from Hesai Technology (NASDAQ:HSAI), enabling wider, farther, and more precise detection.
Hesai Technology has expanded its partnership with Realsee to launch advanced hardware-software solutions that digitally replicate the physical world and commercial environments, driving intelligent transformation across industries.
The company has surpassed 100,000 cumulative deliveries of its JT series lidar—achieved in under five months since launch. It's now the fastest lidar product in the robotics sector to reach this milestone.
Hesai Technology has received ISO 26262 ASIL B functional safety certification for its ATX, a compact, automotive-grade, ultra-high-definition, long-range lidar, from SGS-TÜV.
• HyperStrong (SHSE:688411) signed strategic cooperation agreements with CATL, GENERTEC, and Huachi Kinetic Energy at the SNEC 18th (2025) International Photovoltaic Power Generation and Smart Energy Conference and Exhibition, to advance collaboration in zero-carbon energy, smart manufacturing, joint project development, and more.
The company delivered its liquid-cooling outdoor energy storage cabinet solution to Sienergys' Shanghai supercharging station, boosting EV energy management and tackling peak pricing and transformer overload.
HyperStrong has commissioned a 100MW/200MWh shared energy storage project in Yunnan, combining grid-forming technology with a lithium iron phosphate and vanadium flow hybrid system for high efficiency and long-term stability.
• Sunyur has partnered with Sinochem Holdings to lead the next phase of the digital procurement platform upgrade with a focus on the development of the mall module, following the success of their Phase 1 collaboration in 2023.
• DST has partnered with ZhongAn to launch the Joint Risk Control Laboratory for New Energy Vehicles, building a technology-, data-, and service-driven risk management framework for green logistics.
• Photon Crystal signed a strategic partnership with TÜV Rheinland Greater China to establish a comprehensive quality evaluation system and drive the large-scale application of perovskite technology in the renewable energy sector.
• Tuhu Car (SEHK:9690) has deepened its strategic partnership with Valvoline to drive product innovation, enhance service, and expand the market, offering high-quality, highly compatible car care solutions for Chinese consumers.
• Xiaomi (SEHK:1810) unveiled new products at its "New Beginnings" launch, including Xiaomi OpenWear Stereo Pro, featuring the industry's first five-driver system, sound leakage control, and AI-powered features.
• Roborock (SHSE:688169) brought its cutting-edge smart cleaning technology into the spotlight across Europe with a series of high-impact pop-up events and exhibitions in Germany, France, Sweden, and Poland.
• At MIITE 2025, ROX Motor was featured on the opening ceremony's main screen, highlighting its position as the UAE's No. 1 REEV brand in capability and sales. The ROX 01 Falcon Edition stood out, reflecting leadership and ambition.
• DH-Robotics showcased its technologies and products, including the DH-5-6 Dexterous Hand, at trade shows in the US, Malaysia, and Türkiye, connecting with global partners to explore collaboration and understand overseas demand.
• DeepWay has delivered the first batch of 10 smart new energy heavy trucks to Yunnan Xinyuan Lvneng, marking the official launch of China's first inter-provincial and cross-border new energy heavy truck transportation trunk line.
• During Mexico's Hot Sale, iMile saw an 81.82% YoY surge in parcel volume while delivering over 90% of parcels within 6 days and improving average delivery speed by 25%, showcasing its strong logistics capabilities.
Healthcare
• DP Technology announced that its AI platform, Science Navigator, has partnered with Shenzhen International Science and Technology Information Center to drive a new model of collaboration for regional growth and industrial integration.
The company has partnered with Consun Pharmaceutical Group to advance novel target identification and drug discovery in nephrology, combining Consun's domain expertise with DP Technology's AI for Science platform and capabilities.
DP Technology announced a strategic partnership with Shanghai Jiao Tong University to jointly advance the launch and iteration of an innovative Super Research Platform through the AI-X Research Institute.
The company also announced that its flagship platform, the Bohrium Space Station, has been selected as the official platform for the International Olympiad in Artificial Intelligence competitions in both Australia and Georgia.
• Insilico Medicine signed a Memorandum of Understanding with United Arab Emirates University to boost scientific collaboration, drive biotech innovation in the UAE, and nurture talent across the Middle East.
The company also announced the Nature Medicine publication of Phase 2a results for Rentosertib, a novel TNIK inhibitor for idiopathic pulmonary fibrosis, discovered and designed using a pioneering AI-driven approach.
Insilico Medicine announced the development of novel pan-KRAS inhibitors of new chemotypes, powered by the generative chemistry methods of Chemistry42. The results were published in ACS Medicinal Chemistry Letters.
The company has dosed the first patient in a global multicenter clinical trial to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with a novel structure, for locally advanced and metastatic solid tumors.
Insilico Medicine and its collaborator discovered potent WDR5–MYC interaction inhibitors using AI and physics-based modeling. The research was published in Chemical Biology and Drug Design.
The company announced the release of its Nach01 foundation model on AWS, now available via AWS Marketplace, a major milestone in its collaboration with AWS to provide access to advanced AI tools for drug design.
Insilico Medicine was recognized in the 2025 Nature Index Research Leaders rankings—ranking No. 42 globally and No. 9 in China among biological sciences institutions, with 55 publications including key studies in Nature Biotechnology.
• DK MedTech and Mozarc Medical, a global pioneer in kidney health solutions, are forming a strategic collaboration in the US to jointly address clinical challenges kidney disease patients face during dialysis.
• Alamar Biosciences has partnered with Alzheimer's Disease (AD) Data Initiative and other organization to build one of the largest proteomic datasets in AD, profiling over 40,000 samples using its ultra-sensitive NULISA™ technology.
• HugeMed has announced the official launch of the Tsinghua Chang Gung–HugeMed Urology International Academy, jointly established with Beijing Tsinghua Changgung Hospital.
• Frontage has partnered with VasoDynamics through its wholly owned subsidiary. The collaboration will focus on clinical trials and the future commercialization of specialized dosage forms such as mouthwashes and topical solutions.
• Zai Lab (NASDAQ:ZLAB, SEHK:9688) shared preclinical data at EAACI 2025 showing the potential of ZL-1503, its IL-13/IL-31R bispecific antibody, as a novel treatment for moderate-to-severe atopic dermatitis.
The company also presented updated Phase 1a/1b data on ZL-1310, a potential first-in-class DLL3 antibody-drug conjugate for extensive-stage small cell lung cancer, at the 2025 ASCO Annual Meeting.
• Gan & Lee Pharmaceuticals (SHSE:603087) presented multiple Phase 2 clinical study results for its ultra-long-acting GLP-1 RA, bofanglutide (GZR18), and once-weekly basal insulin analog, GZR4 injection, at the American Diabetes Association (ADA) 85th Scientific Sessions.
The company announced that its rapid-acting insulin aspart was approved by Malaysia's National Pharmaceutical Regulatory Agency, following approvals of basal insulin (insulin glargine) and premixed insulin (insulin aspart 30).
• ArkBio announced that China's National Medical Products Administration has accepted its New Drug Application for Azstarys and granted it Priority Review for the treatment of ADHD in patients aged 6 and above.
• Abbisko Therapeutics (SEHK:2256) announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma.
The company also announced that China's National Medical Products Administration has accepted New Drug Application for pimicotinib as a Class 1 innovative drug for adult patients with Tenosynovial Giant Cell Tumor.
Abbisko Therapeutics has completed the first patient enrollment in an observational study for children with Achondroplasia. This study will collect baseline data for ABSK061, a highly selective small molecule inhibitor of FGFR2/3.
• CanSino Biologics (SEHK:6185, SHSE:688185) and JenKem Technology developed a novel three-component lipid nanoparticle delivery system based on ionizable sterol lipid compounds. The study was published in ACS Applied Materials and Interfaces.
The company announced that its 13-Valent pneumococcal polysaccharide conjugate vaccine iPneucia® has obtained NDA approval from China's National Medical Products Administration.
• SinocellTech (SHSE:688520) has received approval from China's National Medical Products Administration to initiate clinical trials of SCTB39-1, a trispecific antibody immunotherapy candidate, for advanced malignant solid tumors.
• MediLink Therapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration for YL201, an investigational B7H3-targeted antibody drug conjugate for the treatment of small cell lung cancer.
• Schrödinger (NASDAQ:SDGR) shared promising initial Phase 1 data on SGR-1505 in relapsed/refractory B-cell malignancies at the European Hematology Association Annual Congress, demonstrating safety, tolerability, and clinical activity.
• Structure Therapeutics (NASDAQ:GPCR) presented two late-breaking posters at the American Diabetes Association (ADA) 85th Scientific Sessions, highlighting ACCG-2671's potential as a small-molecule obesity treatment and GLP-1's neuroprotective effects in Parkinson's models.
• Researchers from Kobe University, along with GYENNO, published a new federated learning framework, FedOcw, in npj Digital Medicine, boosting cross-lingual Parkinson's detection accuracy while preserving privacy.
At the 18th China Neurologist Association Conference, GYENNO showcased its comprehensive, full-cycle solutions for Parkinson's disease and related conditions, including MATRIX Pro and GYENNO Intelligence.
• InventisBio (SHSE:688382) shared progress on its oral KRASG12C inhibitor garsorasib for treatment of advanced solid tumors, showing promising efficacy and safety in a study led by Prof. Ruihua Xu at Sun Yat-sen University Cancer Center.
• Dearer Group held the official launch ceremony for its new production and R&D facility for colored soft hydrophilic contact lenses in Shanghai. Once operational, the facility is expected to produce around 700 million lenses annually.
• Yanyin Technology has launched China's first CRISPR gene design tool, developed in collaboration with CASTALYSIS BIOSCIENCE. This milestone underscores China's growing contribution of innovative solutions to global life sciences industry.
• Nurotron has officially launched its world-leading 3.0T MRI-compatible cochlear implant system, marking a significant milestone in the advancement of high-end auditory implant technology in China.
At the European Symposium on Pediatric Cochlear Implantation 2025, the company showcased its MRI-compatible cochlear implant and Airum all-in-one speech processor. Prof. Li Yin presented on the clinical benefits of Nurotron's solutions.
• SinoUnited Health has launched the Family Wellness Membership Program, an integrated, full-lifecycle health management solution centered on prevention, continuous care, personalized service, and multidisciplinary collaboration.
• Rendu Biotechnology (SESH:688193) received approval from China's National Medical Products Administration for its Hepatitis B Virus Nucleic Acid Detection Kit (DNA Capture Probe Method), enabling quantitative HBV DNA detection in serum.
• At the International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare Shanghai 2025, Fortune Care launched new home care solutions, Private Care and 360 Patrol, and partnered with COCO, a leader in adult incontinence care.
Fortune Care contributed as a key drafting organization for China's first national standard on brand valuation in senior care, supporting the sector's standardization and high-quality development.
• MEDx has received regulatory approval for a new indication of its PD-L1 companion diagnostic kit, esophageal squamous cell carcinoma (ESCC), following its earlier approval for non-squamous non-small cell lung cancer (nsNSCLC).
• Saints Sages Surgical has officially received US Food and Drug Administration 510(k) clearance for its flagship product, the SA10 Portable Ultrasonic Surgical System and Integrated Scalpels.
• Bioscience has received regulatory approval in China for its Anti-Müllerian Hormone Detection Kit using magnetic particle chemiluminescence. This product advances diagnostics for premature ovarian failure, polycystic ovary syndrome, etc.
• Conexus Bio advised Genrix Bio on its licensing deal with Cullinan Therapeutics for Velinotamig (GR1803), an anti-BCMAxCD3 bispecific antibody. Conexus Bio supported the full BD process and helped secure multiple term sheets.
• Pulnovo Medical successfully completed the first three global commercial PADN procedures at Al Qassimi Hospital in the UAE, marking a major milestone in accelerating global commercialization efforts following CE-MDR certification.
After three successful commercial procedures in the UAE, Pulnovo Medical debuted its PADN technology at CHIP INDIA SUMMIT, highlighting its value as a novel treatment for pulmonary hypertension and a step toward expanding in South Asian market.
The company announced that the Chinese Society of Cardiology has released an Expert Advisory on Percutaneous Pulmonary Artery Denervation (PADN) for the treatment of pulmonary hypertension (PH), published in Cardiology Discovery.
• At the 20th Congress of the World Federation for Ultrasound in Medicine and Biology, VINNO Ultrasound showcased its flagship ULTIMUS series and hosted an expert symposium on URM innovation.
• Koutech collaborated with Professor Yixin Zhang's team at Shanghai Ninth People's Hospital to successfully perform the world's first complex tumor resection and reconstruction surgery assisted by the Kai microsurgical robot.
• At the IPA Congress, Asieris Pharmaceuticals (SHSE:688176) showcased APL-1702, the first non-invasive drug-device combo for cervical precancerous lesions, and APL-1706, the only approved optical imaging agent for bladder cancer.
• Amoy Diagnostics (SZSE:300685) announced the successful validation of its AmoyDx® Master Panel, a comprehensive genomic profiling solution, on the MGI DNBSEQ-G50. The results demonstrated performance comparable to the Illumina NovaSeq 6000.
• At Endoscopy on Air 2025, Dr. Pinghong Zhou and Dr. Mingyan Cai from Zhongshan Hospital of Fudan University performed complex procedures using the AQ-300 4K ultra-high-definition endoscopy system developed by Aohua Endoscopy (SHSE:688212).
• ZD Medical showcased a range of retinal and dry eye solutions at Retina China 2025 and the 26th International Retina Forum, including Luminor-A80, Luminor-D60/D60M, D600 dry eye detector, meibomian gland thermal pulsation system, and more.
• At the 35th Florida International Medical Expo, MicroTech Medical (SEHK:2235) showcased its LinX® Continuous Glucose Monitoring System, Equil™ Patch Insulin Pump, blood glucose monitoring systems, and Pancares® Diabetes Management System.
• At the 35th Florida International Medical Expo, Xinzeyuan showcased its core product lines, from advanced endoscopic components to high-performance disposable devices, highlighting the strength of Chinese medtech on the global stage.
Xinzeyuan showcased its full-spectrum minimally invasive endoscopy solutions, ranging from core components and integrated systems to clinical applications, at the 2025 Medical Endoscopy Technology Development Conference.
• At Sino-Dental® 2025, Bondent unveiled a suite of innovative dental products and solutions, including the 1030X CBCT series and a patented Broken Needle Retrieval Kit.
Bondent, in collaboration with DCARER, has introduced an innovative integrated solution that combines advanced imaging, AR, and real-time tracking to enhance surgical precision.
• At the 2025 China Biomedical Engineering Conference and Medical Innovation Summit, Dr. Xi Yang, CEO of Novaprint Therapeutics, highlighted the NPPM regenerative bone graft and called for deeper collaboration between industry and academia.
Portfolio Awards
• Yunji Technology and its Founder, Chairman, and President Zhi Tao won the top honor "Gold with the Congratulations of the Jury" at the 50th International Exhibition of Inventions Geneva, recognizing its innovation and AI + Embodied Intelligence strategy.
• At the 2025 Biomedical Pitch Competition finals in North America, Epigenic Therapeutics was awarded Third Prize for its pioneering work in epigenetic therapies and innovative business model.
